scholarly journals Irritable bowel syndrome dietary modifications - what to forbid and what to recommend?

2020 ◽  
Vol 10 (8) ◽  
pp. 72
Author(s):  
Agnieszka Kaczyńska ◽  
Małgorzata Wieteska ◽  
Paweł Stanicki ◽  
Julita Szarpak
Keyword(s):  
Irritable Bowel Syndrome ◽  
Irritable Bowel ◽  
Dietary Modifications

scholarly journals Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome

PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0257331
Author(s):  
Sanna Nybacka ◽  
Magnus Simrén ◽  
Stine Störsrud ◽  
Hans Törnblom ◽  
Anna Winkvist ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Dietary Intervention ◽  
Pantothenic Acid ◽  
Gastrointestinal Disorder ◽  
Response To Treatment ◽  
Post Intervention ◽  
Clinical Trial Registration ◽  
Link Type ◽  
Irritable Bowel ◽  
Dietary Modifications

Background Irritable bowel syndrome (IBS) is a multi-faceted gastrointestinal disorder where food intake often triggers symptoms. Metabolomics may provide mechanistical insights to why responses to dietary modifications are diverse. Objective This study aimed to identify metabolite patterns related to dietary intake in patients with IBS, and to identify metabolites driving the separation between responders and non-responders to treatment. Methods Participants were randomized to a low fermentable oligo-, di-, monosaccharide and polyol (FODMAP) diet (LFD) or traditional IBS diet (TID) for four weeks. Fasting serum and urine samples pre- and post-intervention were analyzed using 1H nuclear magnetic resonance (NMR) metabolomics. Response to treatment was defined as a reduction in IBS severity scoring system (IBS-SSS) ≥50. Results Twenty-five individuals in the LFD (13 responders) and 28 in the TID (14 responders) were included in these post hoc analyses. In endpoint samples, significant decreases in polyols and glucose were seen in the LFD. Post-intervention samples revealed that LFD responders had significantly increased levels of 2-hydroxybuturate and decreased levels of glucose and pantothenic acid compared to non-responders. For the TID, only weak multivariate models were identified and a larger diversity in metabolite response compared to the LFD were noted. Conclusions In this study, metabolite patterns between individuals who responded well to an LFD compared to non-responders could be distinguished. This provides new hypotheses for mechanistic actions related to response to dietary modifications, but the results need to be validated in larger cohorts. Clinical trial registration This trial was registered at www.clinicaltrials.gov, registry number NCT02107625.

scholarly journals Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update

2019 ◽  
Author(s):  
Christopher N Andrews ◽  
Marc Bradette
Keyword(s):  
Irritable Bowel Syndrome ◽  
Treatment Options ◽  
Unmet Need ◽  
Work Productivity ◽  
Clinical Trial Data ◽  
Gastrointestinal Disorder ◽  
Lifestyle Modifications ◽  
Individualized Approach ◽  
Irritable Bowel ◽  
Dietary Modifications

Abstract Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder, which impacts the quality of life, work productivity and social activities of patients. Diarrhea-predominant IBS (IBS-D) is one of several subtypes, and accounts for approximately one third of all cases. Currently available treatments are typically unable to alleviate the cardinal symptoms of IBS-D, including abdominal pain and diarrhea, and a clinical unmet need remains for an effective treatment which simultaneously relieves multiple symptoms. Patients may benefit from a multipronged, individualized approach, including dietary modifications, and psychological and pharmacological therapies. The aim of this review is to provide an update on the available and upcoming treatment options for IBS-D in Canada, with reference to the recently updated Canadian IBS consensus guidelines. Initial treatment approaches include lifestyle modifications, dietary modifications, and non-prescription therapies such as peppermint oil. While some medications such as tricyclic antidepressants are also used to treat IBS-D symptoms, eluxadoline and rifaximin are the only two pharmacological therapies approved for the treatment of IBS-D in Canada. Key clinical trial data for the currently available pharmacological options are presented to provide an overview of the efficacy and safety of these agents

Motor and sensory function of the rectum in different types of irritable bowel syndrome

2001 ◽  
Vol 120 (5) ◽  
pp. A399-A399
Author(s):  
J STEENS ◽  
P SCHAAR ◽  
C LAMERS ◽  
A MASCLEE
Keyword(s):  
Irritable Bowel Syndrome ◽  
Sensory Function ◽  
Different Types ◽  
Irritable Bowel

Alterations in regional decreased cerebral blood flow in patients with irritable bowel syndrome-A PET imaging study

2001 ◽  
Vol 120 (5) ◽  
pp. A637-A637
Author(s):  
Y RINGEL ◽  
D DROSSMAN ◽  
T TURKINGTON ◽  
B BRADSHAW ◽  
R COLEMAN ◽  
...  
Keyword(s):  
Blood Flow ◽  
Irritable Bowel Syndrome ◽  
Cerebral Blood Flow ◽  
Pet Imaging ◽  
Imaging Study ◽  
Irritable Bowel

Health releated quality of life in irritable bowel syndrome: A community based study+

2001 ◽  
Vol 120 (5) ◽  
pp. A634-A634 ◽  
Author(s):  
K OLDEN ◽  
W CHEY ◽  
J BOYLE ◽  
E CARTER ◽  
L CHANG
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Community Based ◽  
Irritable Bowel

Differences in productivity QOL, and resource use in newly diagnosed and established irritable bowel syndrome (IBS) patients

2001 ◽  
Vol 120 (5) ◽  
pp. A634-A634
Author(s):  
P JHINGRAN ◽  
J RICCI ◽  
M MARKOWITZ ◽  
S GORDON ◽  
A ASGHARIAN ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Resource Use ◽  
Newly Diagnosed ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document